- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07951047
Intraosseous Injection of Flurbiprofen Axetil for Postoperative Analgesia in Joint Arthroplasty
This single-center, prospective, randomized, double-blind, double-dummy controlled trial aims to evaluate the efficacy and safety of intraosseous versus intravenous flurbiprofen axetil for postoperative pain management in patients undergoing joint arthroplasty.
A total of 240 patients aged 65-80 years undergoing primary unilateral total knee arthroplasty, unicompartmental knee arthroplasty, total hip arthroplasty, or hemiarthroplasty will be enrolled. Participants will be stratified according to surgical procedure and randomly assigned in a 1:1 ratio to receive either intraosseous flurbiprofen axetil with intravenous saline placebo or intravenous flurbiprofen axetil with intraosseous saline placebo. The dose of flurbiprofen axetil will be 50 mg in both groups.
The primary outcome is postoperative pain intensity at rest, assessed using the Visual Analog Scale (VAS) at predefined time points from 1 hour to 6 weeks after surgery. Secondary outcomes include pain during movement, cumulative opioid consumption within 72 hours, length of hospital stay, joint functional recovery, patient satisfaction, patient-controlled analgesia utilization, and adverse events.
This study aims to determine whether intraosseous administration of flurbiprofen axetil provides effective and safe postoperative analgesia compared with conventional intravenous administration following joint arthroplasty.
Panoramica dello studio
Stato
Intervento / Trattamento
Tipo di studio
Iscrizione (Stimato)
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
- Nome: Hua Luo, Dr.
- Numero di telefono: 0576-85190463
- Email: luohua66ry@163.com
Luoghi di studio
-
-
Zhejiang
-
Linhai, Zhejiang, Cina, 317000
- Reclutamento
- No. 150 Ximen Road
-
Contatto:
- Hua Luo
- Numero di telefono: 0576-85190463
- Email: luohua66ry@163.com
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Adults aged 65 to 80 years, regardless of sex.
- Patients scheduled to undergo unilateral joint arthroplasty.
- Patients scheduled for elective surgery with standardized surgical procedures and prosthesis types, consistent with the postoperative analgesia protocol of this study.
- Patients scheduled to receive general anesthesia.
- Patients who are able to understand the study objectives, procedures, and potential risks, voluntarily provide written informed consent, and cooperate with postoperative assessments, including Visual Analog Scale (VAS) pain scores, functional assessments, and patient satisfaction evaluations.
Exclusion Criteria:
- Known hypersensitivity to flurbiprofen, other nonsteroidal anti-inflammatory drugs (NSAIDs), or contraindications to opioids or other medications used in the study.
- Contraindications to NSAID use, including peptic ulcer disease, gastrointestinal bleeding, severe hepatic or renal impairment, or coagulation disorders.
- Severe cardiovascular, hepatic, renal, hematological, or central nervous system diseases that may prevent patients from tolerating general anesthesia or analgesic medications.
- Recent history of gastrointestinal bleeding or active peptic ulcer disease.
- Severe infection, immunodeficiency, or risk of sepsis.
- Psychiatric disorders or cognitive impairment that prevent reliable assessment of postoperative pain intensity or patient satisfaction.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Doppio
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Intraosseous Flurbiprofen
Participants will receive a total dose of 50 mg flurbiprofen axetil via intraosseous administration. For knee arthroplasty, the medication will be administered into the distal femoral and proximal tibial bone cavities. For hip arthroplasty, the medication will be administered into the bone cavity near the greater trochanter. |
Flurbiprofen axetil 50 mg will be administered intraosseously into the distal femoral and proximal tibial bone cavities for knee arthroplasty or near the greater trochanter for hip arthroplasty. Flurbiprofen axetil 50 mg will be administered intravenously. |
|
Comparatore attivo: Intravenous Flurbiprofen Axetil
Participants will receive 50 mg flurbiprofen axetil through intravenous administration. |
Flurbiprofen axetil 50 mg will be administered intraosseously into the distal femoral and proximal tibial bone cavities for knee arthroplasty or near the greater trochanter for hip arthroplasty. Flurbiprofen axetil 50 mg will be administered intravenously. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Visual Analog Scale
Lasso di tempo: At 1, 2, 3, 4, 5, 6, 12, 24, 48, and 72 hours after surgery; postoperative day 7; and postoperative weeks 2 and 6.
|
Postoperative pain intensity at rest will be assessed using the Visual Analog Scale (VAS), ranging from 0 (no pain) to 10 (worst imaginable pain). Higher scores indicate greater pain intensity. |
At 1, 2, 3, 4, 5, 6, 12, 24, 48, and 72 hours after surgery; postoperative day 7; and postoperative weeks 2 and 6.
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Cumulative Opioid Consumption Within 72 Hours
Lasso di tempo: up to 72 hours post-surgery
|
The cumulative dose of opioid analgesics administered during the first 72 hours after surgery will be recorded. Opioid consumption will be converted into morphine milligram equivalents to facilitate comparison between the two treatment groups. |
up to 72 hours post-surgery
|
|
Length of Hospital Stay
Lasso di tempo: From the date of hospital admission to the date of hospital discharge, assessed up to 30 days.
|
The length of hospital stay will be calculated as the number of days from hospital admission to hospital discharge. The duration of hospitalization will be compared between the two treatment groups. Unit: days. |
From the date of hospital admission to the date of hospital discharge, assessed up to 30 days.
|
|
Knee Society Score
Lasso di tempo: At baseline (preoperative assessment), postoperative days 1, 3, and 7, and postoperative weeks 2 and 6.
|
Postoperative knee function will be evaluated using the Knee Society Score (KSS). Scores are recorded at predefined postoperative time points and compared between the two treatment groups to assess functional recovery. Unit: score. |
At baseline (preoperative assessment), postoperative days 1, 3, and 7, and postoperative weeks 2 and 6.
|
|
Patient Satisfaction With Postoperative Analgesia
Lasso di tempo: At hospital discharge.
|
Patient satisfaction with postoperative analgesia will be assessed using a 10-point Numerical Rating Scale (NRS), ranging from 0 (completely dissatisfied) to 10 (completely satisfied). Higher scores indicate greater satisfaction. Unit: score. |
At hospital discharge.
|
|
Cumulative PCA Analgesic Consumption
Lasso di tempo: From PCA initiation to PCA discontinuation, within the first 72 hours after surgery.
|
The cumulative amount of analgesic medication delivered through the patient-controlled analgesia (PCA) system will be recorded from PCA initiation until discontinuation. The total medication consumption will be expressed in milligrams (mg), and the duration of PCA use will also be recorded. Unit: mg. |
From PCA initiation to PCA discontinuation, within the first 72 hours after surgery.
|
|
Incidence of Adverse Events
Lasso di tempo: up to 3 months post-surgery
|
The incidence of adverse events will be assessed in both treatment groups. Recorded events will include gastrointestinal bleeding, renal impairment, cardiovascular events, and wound infection ect. |
up to 3 months post-surgery
|
Collaboratori e investigatori
Sponsor
Pubblicazioni e link utili
Pubblicazioni generali
- Lawal OD, Gold J, Murthy A, Ruchi R, Bavry E, Hume AL, Lewkowitz AK, Brothers T, Wen X. Rate and Risk Factors Associated With Prolonged Opioid Use After Surgery: A Systematic Review and Meta-analysis. JAMA Netw Open. 2020 Jun 1;3(6):e207367. doi: 10.1001/jamanetworkopen.2020.7367.
- Hah JM, Bateman BT, Ratliff J, Curtin C, Sun E. Chronic Opioid Use After Surgery: Implications for Perioperative Management in the Face of the Opioid Epidemic. Anesth Analg. 2017 Nov;125(5):1733-1740. doi: 10.1213/ANE.0000000000002458.
- McNamara CA, Laurita J, Lambert BS, Sullivan TC, Clyburn TA, Incavo SJ, Park KJ. A multimodal intraosseous infusion of morphine and ketorolac decreases early postoperative pain and opioid consumption following total knee arthroplasty. Knee. 2023 Aug;43:129-135. doi: 10.1016/j.knee.2023.06.002. Epub 2023 Jul 1.
- Zhao C, Liao Q, Yang D, Yang M, Xu P. Advances in perioperative pain management for total knee arthroplasty: a review of multimodal analgesic approaches. J Orthop Surg Res. 2024 Dec 19;19(1):843. doi: 10.1186/s13018-024-05324-4.
- Hafeez K, Umar M, Desai V. Factors delaying mobilization after hip and knee arthroplasty. Int J Health Sci (Qassim). 2024 Sep-Oct;18(5):4-7.
- Haffar A, Fillingham YA, Breckenridge L, Gursay D, Lonner JH. Meloxicam versus Celecoxib for Postoperative Analgesia after Total Knee Arthroplasty: Safety, Efficacy and Cost. J Am Acad Orthop Surg Glob Res Rev. 2022 Apr 5;6(4):e22.00032. doi: 10.5435/JAAOSGlobal-D-22-00032.
- Ng JS, van der Werf B, Nicholson L, Farrington W, Young SW. The AAHKS Clinical Research Award: Intraosseous Regional Diclofenac for Postoperative Pain Management in Total Knee Arthroplasty. J Arthroplasty. 2025 Sep;40(S19):S18-S27. doi: 10.1016/j.arth.2025.05.013. Epub 2025 May 9.
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- K20251066
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .